BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1373 related articles for article (PubMed ID: 24401223)

  • 1. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
    Sanyal AJ
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():48-51. PubMed ID: 16225473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime.
    Blonsky JJ; Harrison SA
    Aliment Pharmacol Ther; 2008 May; 27(10):855-65. PubMed ID: 18315584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
    Ascha MS; Hanouneh IA; Lopez R; Tamimi TA; Feldstein AF; Zein NN
    Hepatology; 2010 Jun; 51(6):1972-8. PubMed ID: 20209604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
    Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
    Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C and diabetes: the inevitable coincidence?
    Lonardo A; Adinolfi LE; Petta S; Craxì A; Loria P
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):293-308. PubMed ID: 19344243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].
    Lonardo A; Loria P; Adinolfi LE; Andreana A; Ruggiero G; Carulli N
    Ann Ital Med Int; 2005; 20(1):10-22. PubMed ID: 15859390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
    Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Targher G; Lonardo A
    Int J Mol Sci; 2016 Mar; 17(3):355. PubMed ID: 27005620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.
    Sanyal AJ; Banas C; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Heuman D; Coterrell A; Fisher RA; Contos MJ; Mills AS
    Hepatology; 2006 Apr; 43(4):682-9. PubMed ID: 16502396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.
    Pekow JR; Bhan AK; Zheng H; Chung RT
    Cancer; 2007 Jun; 109(12):2490-6. PubMed ID: 17487861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.
    García-Monzón C; Lo Iacono O; Mayoral R; González-Rodríguez A; Miquilena-Colina ME; Lozano-Rodríguez T; García-Pozo L; Vargas-Castrillón J; Casado M; Boscá L; Valverde AM; Martín-Sanz P
    J Hepatol; 2011 Jan; 54(1):142-52. PubMed ID: 20888662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.
    Baffy G; Brunt EM; Caldwell SH
    J Hepatol; 2012 Jun; 56(6):1384-91. PubMed ID: 22326465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications.
    Adinolfi LE; Durante-Mangoni E; Zampino R; Ruggiero G
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():52-5. PubMed ID: 16225474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.